Interleukins and cancer immunotherapy.
Cancer is a complex disease with interactions between normal and neoplastic cells. Since current therapies for cancer largely rely on drugs or radiation that kill dividing cells or block cell division, these treatments may have severe side effects on normal proliferating cells in patients with cancer. Therefore, the potential for treatment of cancer patients by immunologic approaches, which may be specific for tumors and will not injure most normal cells, has great promise. Cancer immunotherapy aims to augment the weak host immune response to developing tumors. One strategy is to utilize cytokines such as IL-2. More recently, several exciting new interleukins have been characterized that have considerable promise for future immunotherapy. The promise of cancer immunotherapy largely depends upon the identification of these novel interleukins. This review provides an overview of the antitumor effects of relatively new interleukins as potential therapeutic agents applicable for cancer immunotherapy.
Yoshimoto
Takayuki
T
Intractable Disease Research Center, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. yoshimot@tokyo-med.ac.jp
Morishima
Noriko
N
Okumura
Masae
M
Chiba
Yukino
Y
Xu
Mingli
M
Mizuguchi
Junichiro
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002450:Cell Communication; D006801:Humans; D007167:Immunotherapy; D007378:Interleukins / Q000276:immunology / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D059016:Tumor Microenvironment / Q000276:immunology
D000911:Antibodies, Monoclonal; D007378:Interleukins